JDS Therapeutics LLC

Lindus Health will use their technology platform and machcine learning to manage trials from start to finish aiming to help treatments reach patients quickly in a bid to improve and extend lives. The news comes as the company reveals it has to date raised $6 million from investors, including from Firstminute, Seedcamp and Peter Thiel (PayPal co-founder and the first outside investor in Facebook), to accelerate their use of machine learning and data science to revolutionise clinical trials. Lindus Health is also announcing that it has received an Innovate UK Smart Grant, part of UK Research and Innovation (UKRI), worth almost £500,000, with their work in machine learning and data science described by UKRI assessors as a ‘​​hugely valuable and game-changing project’. Lindus Health says its technology speeds up the time it takes to approve treatments and get them to market, with their trials to date having been completed three times more quickly than the old-fashioned industry standard. Lindus has delivered more than 80 trials for treatments across the US, UK and Europe and will next be working with healthcare company, Pharmanovia, to evaluate the safety and efficacy of a treatment for patients with severe insomnia in a real-world setting. It will use digital technology to find hard-to-reach insomnia patients. Working with Oto, a provider of digital tinnitus programs, the company will run a trial for 200 people evaluating their digital tinnitus solution against in-person therapy. googletag.cmd.push(function () { googletag.display('text-ad1'); }); Additionally, Lindus is partnering with Berlin-based start-up Dopavision to trial the MyopiaX treatment for children affected by progressive short sightedness. This aims to increase dopamine levels in the retina to slow the progression of the condition. This year, Lindus Health is also launching a trial aimed at treating and reversing type 2 diabetes with George Medicines and a trial aimed at reducing symptoms of menopause, with US-based Bonafide Health, whose parent company is JDS Therapeutics. Launched in 2021 by Michael Young and Meri Beckwith, Lindus Health has already worked with 20,000 patients to find new treatments for chronic conditions. Co-founder of Lindus Health, Michael Young, said: “Clinical trials are the biggest bottleneck to improving human health. We’re working with high-growth companies developing the next wave of breakthrough treatments to accelerate the clinical trials process. “It’s fantastic to be working with the Government and industry pioneers to revolutionise clinical trials to deliver treatments to benefit patients more quickly. “From monitoring trial data in real time to using machine learning to predict trial outcomes and make improvements to trial designs in advance, we want to simplify and accelerate the trials process and put patients first.”

Early Data from Soft Launch Period Shows Improved Sales and Favorable Customer Ratings VANCOUVER, BC, April 20, 2023 /PRNewswire/ - Hapbee Technologies, Inc. (TSXV: HAPB) (OTCQB: HAPBF) (FSE: HA1) ("Hapbee" or the "Company") the wearable, wellness technology company and creator of the Hapbee Smart Sleep Pad, has released results from its recent launch of a dedicated brand store on leading online marketplace Amazon.com. Hapbee leverages patented, magnetic-field technology that helps people optimize their sleep, performance, and moods. Ultra-low frequency electromagnetic signals are derived from compounds like caffeine, nicotine and melatonin and are re-played digitally through Hapbee-powered devices, such as the Smart Sleep Pad and Neckband without the side-effects or dependencies that might otherwise result from the substances. The Company had previously experimented with selling its Neckband device as a discrete product on Amazon. In February 2023, Hapbee soft-launched a completely redesigned dedicated wellness store on the leading e-commerce marketplace – featuring both the Neckband and the new Smart Sleep Pad. The purpose of the soft-launch period was to gauge customer reaction within Amazon, to fine-tune content and messaging, and to optimize promotional strategy while limiting exposure to a portion of Amazon's consumer audience. Since re-launching in mid-February – Hapbee has seen an 8X increase in monthly sales on Amazon when compared to Amazon monthly sales in Q4 2022 - despite limited exposure during the soft-launch period. Customer reaction has been positive, with an average rating of 4.1 (out of 5) for Hapbee from buyers submitting reviews on the platform. "Amazon represents the opportunity to add an important distribution channel for Hapbee as a complement to our own website as many online customers prefer the ease, convenience and confidence of shopping on Amazon," said Yona Shtern, CEO of Hapbee. "Amazon is also a pre-eminent platform for product search and discovery, which makes our positive customer ratings so encouraging as we plan for our expansion moving forward." Hapbee's re-launched Amazon presence is being managed through a partnership by The JDS Group (JDS) - a brand management & marketing company that specializes in helping consumer-facing brands accelerate their growth through implementation of Amazon and online marketplace strategies. "We greatly appreciate our affiliation with Hapbee and are excited about contributing to their growth," said Anthony Fallon, President of JDS. "This partnership will really help to maximize the sleep quality of many customers all across Amazon's platform." About Hapbee Hapbee is a digital wellness technology company that aims to help people take control of how they sleep, perform and feel. Hapbee's digital wellness library of Wellness Routines utilizes patented ultra-low radio frequency energy (ulRFE®), designed to help optimize users' sleep, productivity and focus, recovery, and downtime. Hapbee devices and subscriptions are available for purchase at Hapbee.com and through a growing network of select distributors. You can learn more about how Hapbee works at Forward-Looking Statements Certain statements included in this news release constitute forward-looking information or statements (collectively, "forward-looking statements"), including those identified by the expressions "anticipate", "believe", "plan", "estimate", "expect", "intend", "may", "should" and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This news release contains forward-looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict. Such statements and information are based on numerous assumptions regarding the Company's ability and intended timing to complete its Filings. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement, and are subject to various risks, uncertainties and assumptions which include, but are not limited to, those described in Hapbee's annual information form dated May 2, 2022, as well as those described in Hapbee's other disclosure documents, copies of which are available on SEDAR at , and could cause actual events or results to differ materially from those projected in any forward-looking statements. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Readers should not place undue reliance on the Company's forward-looking statements. Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. SOURCE Hapbee Technologies Inc.

LIBERTYVILLE, Ill., Oct. 12, 2022 /PRNewswire/ -- Hollister Incorporated, a global medical device company, announces the publication of a patient support program study through the Journal of Wound Ostomy & Continence Nursing (JWOCN). The study, titled A Cross-Sectional Survey Reporting on the Value of Patient-Centered Ostomy Programs: A Smooth Transition After Ostomy Surgery, focuses on connecting support service interactions to better results in areas of stoma barrier leakage, proper fit, and skin health1. In 2004, Hollister created Secure Start ℠ services, the first transition service of its kind to support people with an ostomy throughout the continuum of care. Our commitment to our customers has remained constant since inception of the service over 18 years ago; to make life more rewarding and dignified for people who use our products and services. Secure Start services continues to show how our post-surgical ostomy support programs help patients increase their knowledge and reduce unplanned care visits. The cross-sectional survey of nearly 300 U.S. adults within six-months of ostomy surgery revealed some interesting results. Patients enrolled in Secure Start services – and who engage with the program at least twice – reported a higher level of understanding regarding education, skin care, pouching system and accessory use and supplier assistance1. "Stoma construction is challenging, and less-than-ideal stomas are creating many downstream management problems for people with ostomies. The ability to have a resource to provide initial education or reinforcement of education has helped prevent readmissions," said Laurie McNichol, MSN, RN, CNS, GNP, CWOCN, CWON-AP, FAAN, WOC Nurse, Cone Health, Greensboro, North Carolina. "This program puts repeatable, predictable ostomy pouching wear times and healthy skin above all else, no matter what products (or from what manufacturer) the patient is using. The fact that this knowledge is shared, and suggestions are evidence based and aligned with WOC nursing guidance is invaluable to patient recovery and maintenance." Hollister Secure Start services provides a lifetime of personalized support and condition specific education to people who use our products and services and to help them adjust to the physical and lifestyle changes they're navigating. "As we continue to strive to help support better patient outcomes, we wanted to learn more about the ongoing experience of those who have enrolled in Secure Start services," said Jayme Schuler, Hollister Incorporated Director of Secure Start services. "This study reflects the support of our Consumer Service Advisors, who serve as product experts, that are dedicated to helping patients with the tools and resources they need throughout their journey to get back to living their life, their way." About Hollister Incorporated Hollister Incorporated is an independent, employee-owned company that develops, manufactures, and markets healthcare products worldwide. The company develops and manufactures products for ostomy care, continence care and critical care, and also develops educational support materials for patients and healthcare professionals. Headquartered in Libertyville, Illinois, it has manufacturing and distribution centers on three continents and sells in nearly 80 countries. Hollister is a wholly owned subsidiary of The Firm of John Dickinson Schneider Inc. (JDS Inc.), a 100-year-old company. Hollister is guided by the shared Mission of JDS Inc., to make life more rewarding and dignified for people who use its products and services. . Media Contact Jennifer McGrath Corporate Communications [email protected] +1.224.358.7033